Patents Assigned to Celgene Corporation
  • METHODS FOR MEASURING SMALL MOLECULE AFFINITY TO CEREBLON
    Publication number: 20210102938
    Abstract: A complex comprises a CRBN having a europium-anti-his antibody on the N-terminus of the CRBN, and a Cy5-conjugated small molecule, wherein the Cy5-conjugated small molecule binds the CRBN, and uses thereof for identifying therapeutic compounds.
    Type: Application
    Filed: September 18, 2020
    Publication date: April 8, 2021
    Applicant: CELGENE CORPORATION
    Inventors: Philip Paul CHAMBERLAIN, Mary MATYSKIELA, Godrej KHAMBATTA
  • METHODS FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA AND THE USE OF BIOMARKERS AS A PREDICTOR TO RESPONSIVENESS TO DRUGS
    Publication number: 20210102257
    Abstract: In one aspect, provided herein are methods for predicting the responsiveness of DLBCL patients to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classfiers that correlate with responsiveness to one of these drugs. In another aspect, provided herein are methods for treating a DLBCL patient determined to be responsive to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classifiers (or output thereof) that correlate with responsiveness to one of these drugs.
    Type: Application
    Filed: May 18, 2020
    Publication date: April 8, 2021
    Applicant: Celgene Corporation
    Inventors: Matthew William Burnell Trotter, Alberto Risueno Perez, Michael Pourdehnad, Anita Gandhi, Patrick Hagner
  • Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile
    Patent number: 10969381
    Abstract: A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: April 6, 2021
    Assignee: Celgene Corporation
    Inventors: Joshua Hansen, Courtney G. Havens, Antonia Lopez-Girona, Gang Lu, Lilly L. Wong
  • Modified T lymphocytes comprising a BAFF antibody-inducible caspase and methods of apoptosis
    Patent number: 10967005
    Abstract: Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: April 6, 2021
    Assignee: CELGENE CORPORATION
    Inventors: Stewart Abbot, Tianjian Li, Bitao Liang
  • COMBINATION THERAPY USING ADOPTIVE CELL THERAPY AND CHECKPOINT INHIBITOR
    Publication number: 20210069246
    Abstract: Provided are methods, compositions, uses and articles of manufacture of combination therapies involving immunotherapies, such as adoptive cell therapy, e.g., T cell therapy, and the use of a checkpoint inhibitor, such as an anti-PD-L1 antibody or antigen-binding fragment thereof for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is a non-Hodgkin lymphoma (NHL), such as relapsed or refractory NHL or specific NHL subtype.
    Type: Application
    Filed: January 31, 2019
    Publication date: March 11, 2021
    Applicant: Celgene Corporation
    Inventors: Stanley R. FRANKEL, Jens HASSKARL, Oliver MANZKE
  • Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
    Patent number: 10919873
    Abstract: Provided herein is a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate. Pharmaceutical compositions comprising the crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate are also disclosed.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: February 16, 2021
    Assignee: Celgene Corporation
    Inventor: Jerry Lee Atwood
  • Treatment of immune-related and inflammatory diseases
    Patent number: 10919883
    Abstract: Provided herein are methods of using compounds and compositions for modulating leukocytic activity, including activity of B cells and/or T cells monocytes, macrophages, and other lymphoid or myeloid-derived cell types, in immune-related diseases or inflammatory diseases. Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.
    Type: Grant
    Filed: August 8, 2013
    Date of Patent: February 16, 2021
    Assignee: Celgene Corporation
    Inventors: Peter H. Schafer, Rajesh Chopra, Anita Gandhi
  • Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide
    Patent number: 10898488
    Abstract: Provided are formulations and dosage forms of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide, alternatively named (1s,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: January 26, 2021
    Assignee: Celgene Corporation
    Inventors: Scott Bone, Tracy Lee Gaebele, Yu Pu, Lianfeng Huang
  • METHODS OF TREATING HEMATOLOGICAL DISORDERS, SOLID TUMORS, OR INFECTIOUS DISEASES USING NATURAL KILLER CELLS
    Publication number: 20210008109
    Abstract: Provided herein are methods of treating a hematological disorder, a solid tumor, or an infectious disease in a subject in need thereof using natural killer cells in combination with a second agent, or using natural killer cells with genetic modifications for target specificity and/or homing specificity.
    Type: Application
    Filed: February 18, 2020
    Publication date: January 14, 2021
    Applicant: CELGENE CORPORATION
    Inventors: Lin KANG, Xiaokui ZHANG, Jeffrey HARRIS, Vladimir JANKOVIC
  • COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON AND OTHER E3 UBIQUITIN LIGASES
    Publication number: 20210003557
    Abstract: Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
    Type: Application
    Filed: July 21, 2020
    Publication date: January 7, 2021
    Applicant: Celgene Corporation
    Inventors: Brian E. Cathers, Philip Chamberlain, Antonia Lopez-Girona, Gang Lu
  • COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON AND OTHER E3 UBIQUITIN LIGASES
    Publication number: 20210000813
    Abstract: Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
    Type: Application
    Filed: April 17, 2020
    Publication date: January 7, 2021
    Applicant: Celgene Corporation
    Inventors: Philip Chamberlain, Brian E. Cathers, Antonia Lopez-Girona
  • METHODS OF EXPANDING T CELLS
    Publication number: 20200407681
    Abstract: Provided herein are methods in the field of cell culture, specifically of culture and expansion of immune cells, e.g., T lymphocytes.
    Type: Application
    Filed: April 15, 2020
    Publication date: December 31, 2020
    Applicant: CELGENE CORPORATION
    Inventors: Stewart Abbot, Willard Foss, Thomas Daniel
  • Anti-CD47 antibodies and uses thereof
    Patent number: 10870699
    Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to human CD47. Also provided are uses and methods, such as therapeutic methods, diagnostic methods, and methods of making such antibodies.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: December 22, 2020
    Assignee: CELGENE CORPORATION
    Inventors: Aaron Sato, Ryan Stafford, Junhao Yang
  • Solid forms comprising 4-amino-2-(2,6- dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereof
    Patent number: 10835522
    Abstract: Provided herein are solid forms comprising (a) 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and (b) a coformer. Pharmaceutical compositions comprising the solid forms (e.g., cocrystals) and methods for treating, preventing and managing various disorders are also disclosed.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: November 17, 2020
    Assignee: Celgene Corporation
    Inventors: G. Patrick Stahly, David Jonaitis, Ho-Wah Hui, Kevin J. Klopfer
  • Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
    Patent number: 10830762
    Abstract: Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
    Type: Grant
    Filed: December 27, 2016
    Date of Patent: November 10, 2020
    Assignee: CELGENE CORPORATION
    Inventors: Brian E. Cathers, Philip Chamberlain, Antonia Lopez-Girona, Gang Lu
  • Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
    Patent number: 10829472
    Abstract: Provided herein is a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate. Pharmaceutical compositions comprising the crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate are also disclosed.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: November 10, 2020
    Assignee: Celgene Corporation
    Inventor: Jerry Lee Atwood
  • Methods for measuring small molecule affinity to cereblon
    Patent number: 10816544
    Abstract: A complex comprises a CRBN having a europium-anti-his antibody on the N-terminus of the CRBN, and a Cy5-conjugated small molecule, wherein the Cy5-conjugated small molecule binds the CRBN, and uses thereof for identifying therapeutic compounds.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: October 27, 2020
    Assignee: CELGENE CORPORATION
    Inventors: Philip Paul Chamberlain, Mary Matyskiela, Godrej Khambatta
  • METHODS FOR TREATING CANCER AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO THERAPIES
    Publication number: 20200333340
    Abstract: A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is a compound of Formula I:
    Type: Application
    Filed: April 3, 2020
    Publication date: October 22, 2020
    Applicant: CELGENE CORPORATION
    Inventors: Ellen FILVAROFF, Antonia LOPEZ-GIRONA, Gang LU
  • METHODS AND COMPOSITIONS FOR REDUCTION OF IMMUNOGENICITY
    Publication number: 20200330590
    Abstract: Provided herein are methods and uses involving the combination of an anti-CD20 antibody, e.g., rituximab with a protein therapeutic, for example, an antibody (e.g., an antibody that specifically binds to human CD47).
    Type: Application
    Filed: March 26, 2018
    Publication date: October 22, 2020
    Applicant: CELGENE CORPORATION
    Inventors: Jeffrey C. Johnson, Lawrence Dearth, Haralambos Vassiliou, Jeonghoon Sun, Kandasamy Hariharan
  • Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
    Patent number: 10781199
    Abstract: Provided herein is a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate. Pharmaceutical compositions comprising the crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate are also disclosed.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: September 22, 2020
    Assignee: Celgene Corporation
    Inventor: Jerry Lee Atwood